Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation

Journal of Neuroscience

Volumn 32, Issue 16, 2012, Pages 5385-5397

  Sakrikar, Dhananjay ^a   Mazei Robison, Michelle S ^a,e   Mergy, Marc A ^a   Richtand, Nathan W ^c   Han, Qiao ^a   Hamilton, Peter J ^a   Bowton, Erica ^a   Galli, Aurelio ^a   Veenstra Vanderweele, Jeremy ^a,b   Gill, Michael ^d   Blakely, Randy D ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DOPAMINE TRANSPORTER; FLOTILLIN 1; GANGLIOSIDE GM1; PROTEIN KINASE C; PROTEIN VARIANT;

ADOLESCENT; AMPEROMETRY; ARTICLE; ATTENTION DEFICIT DISORDER; BIOTINYLATION; CHILD; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTERNALIZATION; MAJOR CLINICAL STUDY; MALE; MUTAGENESIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; WESTERN BLOTTING;

ADOLESCENT; AMPHETAMINE; ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BACTERIAL PROTEINS; BENZYLAMINES; BIOTINYLATION; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL LINE, TRANSFORMED; CHILD; CHILD, PRESCHOOL; CHOLERA TOXIN; COHORT STUDIES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMISTRY; FEMALE; HUMANS; IMMUNOPRECIPITATION; LUMINESCENT PROTEINS; MALE; MEMBRANE MICRODOMAINS; MEMBRANE PROTEINS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; SULFONAMIDES; TRANSFECTION; TRITIUM;

EID: 84859780639     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.6033-11.2012     Document Type: Article

References (66)

1. Adkins EM, Samuvel DJ, Fog JU, Eriksen J, Jayanthi LD, Vaegter CB, Ramamoorthy S, Gether U (2007) Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. Biochemistry 46:10484-10497.
2. Amanchy R, Periaswamy B, Mathivanan S, Reddy R, Tattikota SG, Pandey A (2007) A curated compendium of phosphorylation motifs. Nat Biotechnol 25:285-286.
3. Apparsundaram S, Galli A, DeFelice LJ, Hartzell HC, Blakely RD (1998) Acute regulation of norepinephrine transport: I. Protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. J Pharmacol Exp Ther 287:733-743.
4. Apparsundaram S, Sung U, Price RD, Blakely RD (2001) Traffickingdependent and -independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells. J Pharmacol Exp Ther 299:666-677.
5. Baucum AJ 2nd, Jalan-Sakrikar N, Jiao Y, Gustin RM, Carmody LC, Tabb DL, Ham AJ, Colbran RJ (2010) Identification and validation of novel spinophilin-associated proteins in rodent striatum using an enhanced ex vivo shotgun proteomics approach. Mol Cell Proteomics 9:1243-1259.
6. Bellgrove MA, Johnson KA, Barry E, Mulligan A, Hawi Z, Gill M, Robertson I, Chambers CD (2009) Dopaminergic haplotype as a predictor of spatial inattention in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 66:1135-1142.
7. Binda F, Dipace C, Bowton E, Robertson SD, Lute BJ, Fog JU, Zhang M, Sen N, Colbran RJ, Gnegy ME, Gether U, Javitch JA, Erreger K, Galli A (2008) Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol Pharmacol 74:1101-1108.
8. Bjerggaard C, Fog JU, Hastrup H, Madsen K, Loland CJ, Javitch JA, Gether U (2004) Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions. J Neurosci 24:7024-7036.
9. Bobb AJ, Castellanos FX, Addington AM, Rapoport JL (2005) Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B Neuropsychiatr Genet 132B:109-125.
10. Boudanova E, Navaroli DM, Melikian HE (2008a) Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent. Neuropharmacology 54:605-612.
11. Boudanova E, Navaroli DM, Stevens Z, Melikian HE (2008b) Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization. Mol Cell Neurosci 39:211-217.
12. Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N, Jessen T, Colbran RJ, Caron MG, Javitch JA, Blakely RD, Galli A (2010) Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci 30:6048-6057.
13. Carlsson A (1987) Perspectives on the discovery of central monoaminergic neurotransmission. Annu Rev Neurosci 10:19-40.
14. Chase TN, Oh JD, Blanchet PJ (1998) Neostriatal mechanisms in Parkinson's disease. Neurology 51:S30-S35.
15. Chen R, Furman CA, Gnegy ME (2010) Dopamine transporter trafficking: rapid response on demand. Future Neurol 5:123.
16. Cremona ML, Matthies HJ, Pau K, Bowton E, Speed N, Lute BJ, Anderson M, Sen N, Robertson SD, Vaughan RA, Rothman JE, Galli A, Javitch JA, Yamamoto A (2011) Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. Nat Neurosci 14:469-477.
17. Deken SL, Wang D, Quick MW (2003) Plasma membrane GABA transporters reside on distinct vesicles and undergo rapid regulated recycling. J Neurosci 23:1563-1568.
18. Fog JU, Khoshbouei H, Holy M, Owens WA, Vaegter CB, Sen N, Nikandrova Y, Bowton E, McMahon DG, Colbran RJ, Daws LC, Sitte HH, Javitch JA, Galli A, Gether U (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51:417-429.
19. Foster JD, Vaughan RA (2011) Palmitoylation controls dopamine transporter kinetics, degradation, and protein kinase C-dependent regulation. J Biol Chem 286:5175-5186.
20. Foster JD, Adkins SD, Lever JR, Vaughan RA (2008) Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J Neurochem 105:1683-1699.
21. Furman CA, Chen R, Guptaroy B, Zhang M, Holz RW, Gnegy M (2009) Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy. J Neurosci 29:3328-3336.
22. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M (1997) Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 2:311-313.
23. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
24. Gizer IR, Ficks C, Waldman ID (2009) Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 126:51-90.
25. 2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter. Mol Pharmacol 66:137-143.
26. Groen JL, Kawarai T, Toulina A, Rivoiro C, Salehi-Rad S, Sato C, Morgan A, Liang Y, Postuma RB, St George-Hyslop P, Lang AE, Rogaeva E (2004) Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. Neurosci Lett 372:226-229.
27. Holton KL, Loder MK, Melikian HE (2005) Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat Neurosci 8:881-888.
28. Hong WC, Amara SG (2010) Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J Biol Chem 285:32616-32626.
29. Kahlig KM, Javitch JA, Galli A (2004) Amphetamine regulation of dopamine transport. Combined measurements of transporter currents and transporter imaging support the endocytosis of an active carrier. J Biol Chem 279:8966-8975.
30. Kahlig KM, Lute BJ, Wei Y, Loland CJ, Gether U, Javitch JA, Galli A (2006) Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol Pharmacol 70:542-548.
31. Kaye DM, Gruskin S, Smith AI, Esler MD (2000) Nitric oxide mediated modulation of norepinephrine transport: identification of a potential target for S-nitrosylation. Br J Pharmacol 130:1060-1064.
32. +-dependent mechanism. J Biol Chem 278:12070-12077.
33. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, Javitch JA (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2:E78.
34. Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I, McCarron M, O'Donnell D, Fitzgerald M, Gill M (2003) Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet 121B:50-54.
35. Kurian MA, Zhen J, Cheng SY, Li Y, Mordekar SR, Jardine P, Morgan NV, Meyer E, Tee L, Pasha S, Wassmer E, Heales SJ, Gissen P, Reith ME, Maher ER (2009) Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonismdystonia. J Clin Invest 119:1595-1603.
36. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ, Arango JC (1996) The E280A presenilin 1 Alzheimer mutation produces increasedAbeta 42 deposition and severe cerebellar pathology. Nat Med 2:1146-1150.
37. Li Q, Liu Z, Monroe H, Culiat CT (2002) Integrated platform for detectionof DNA sequence variants using capillary array electrophoresis. Electrophoresis 23:1499-1511.
38. Loder MK, Melikian HE (2003) The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem 278:22168-22174.
39. Mazei-Robison MS, Blakely RD (2005) Expression studies of naturally occurring human dopamine transporter variants identifies a novel state of transporter inactivation associated with Val382Ala. Neuropharmacology 49:737-749.
40. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD (2005) Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 49:724-736.
41. Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH, Galli A, Blakely RD (2008) Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci 28:7040-7046.
42. Miranda M, Dionne KR, Sorkina T, Sorkin A (2007) Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter. Mol Biol Cell 18:313-323.
43. Nagahara N, Matsumura T, Okamoto R, Kajihara Y (2009) Protein cysteine modifications: (1) medical chemistry for proteomics. Curr Med Chem 16:4419-4444.
44. Navaroli DM, Stevens ZH, Uzelac Z, Gabriel L, King MJ, Lifshitz LM, Sitte HH, Melikian HE (2011) The plasma membrane-associated GTPase Rin interacts with the dopamine transporter and is required for protein kinase C-regulated dopamine transporter trafficking. J Neurosci 31:13758-13770.
45. Netto LE, de Oliveira MA, Monteiro G, Demasi AP, Cussiol JR, Discola KF, Demasi M, Silva GM, Alves SV, Faria VG, Horta BB (2007) Reactive cysteine in proteins: protein folding, antioxidant defense, redox signaling and more. Comp Biochem Physiol C Toxicol Pharmacol 146:180-193.
46. Qi Y, Wang JK, McMillian M, Chikaraishi DM (1997) Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. J Neurosci 17:1217-1225.
47. Qian Q, Wang Y, Zhou R, Li J, Wang B, Glatt S, Faraone SV (2003) Familybased and case-control association studies of catechol-O-methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. Am J Med Genet B Neuropsychiatr Genet 118B:103-109.
48. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223.
49. Robbins TW (2003) Dopamine and cognition. Curr Opin Neurol 16 [Suppl 2]:S1-S2.
50. Sandvig K, van Deurs B (2000) Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J 19:5943-5950.
51. Sauer B (1994) Site-specific recombination: developments and applications. Curr Opin Biotechnol 5:521-527.
52. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A 97:6850-6855.
53. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569-1572.
54. Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387:569-572.
55. Smith AK, Mick E, Faraone SV (2009) Advances in genetic studies of attention- deficit/hyperactivity disorder. Curr Psychiatry Rep 11:143-148.
56. Sorkina T, Doolen S, Galperin E, Zahniser NR, Sorkin A (2003) Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J Biol Chem 278:28274-28283.
57. Sorkina T, Miranda M, Dionne KR, Hoover BR, Zahniser NR, Sorkin A (2006) RNA interference screen reveals an essential role of Nedd4-2 in dopamine transporter ubiquitination and endocytosis. J Neurosci 26:8195-8205.
58. Steiner JA, Carneiro AM, Blakely RD (2008) Going with the flow: trafficking-dependent and -independent regulation of serotonin transport. Traffic 9:1393-1402.
59. Steiner JA, Carneiro AM, Wright J, Matthies HJ, Prasad HC, Nicki CK, Dostmann WR, Buchanan CC, Corbin JD, Francis SH, Blakely RD (2009) cGMP-dependent protein kinase Ialpha associates with the antidepressantsensitive serotonin transporter and dictates rapid modulation of serotonin uptake. Mol Brain 2:26.
60. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433.
61. Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, Taylor E, Casey BJ, Castellanos FX, Wadhwa PD (2007) Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 17:39-59.
62. Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, Caron MG (2001) Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30:121-134.
63. Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao WD, Caron MG (2003) Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem 278:2731-2739.
64. +/calmodulin-dependent kinase IIdependent mechanism. Mol Pharmacol 71:835-842.
65. Winsberg BG, Comings DE (1999) Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 38:1474-1477.
66. Zorzano A, Sevilla L, Camps M, Becker C, Meyer J, Kammermeier H, MuÑoz P, Gumà A, Testar X, Palacín M, Blasi J, Fischer Y (1997) Regulation of glucose transport, and glucose transporters expression and trafficking in the heart: studies in cardiac myocytes. Am J Cardiol 80:65A-76A.